Diabetes
About 589 million adults worldwide lived with diabetes in 2024 on IDF estimates — more than five times the 108 million of 1980, although the two figures come from different sources. About 90% have Type 2 diabetes. Prevalence is now highest in the Middle East and North Africa, the Western Pacific, and South Asia. IDF attributes about 3.4 million deaths a year to diabetes, nearly twice tuberculosis and malaria combined; WHO counts about 1.6 million where diabetes is the underlying cause.
Key insights
More than five-fold rise since 1980
The number of adults with diabetes rose from ~108 million (1980) to ~589 million (2024). The rise tracks obesity and population aging, plus more accurate diagnosis. Type 2 diabetes accounts for the bulk of the increase. The largest absolute growth has been in middle-income countries — China, India, Indonesia, Pakistan, Brazil, Mexico together hold over half of the world's diabetes cases.
Geographic shift
Highest prevalence: Pakistan (31%), Pacific Island nations (Marshall Islands, Nauru, Tuvalu — over 20%), Gulf states (Kuwait 25%, Saudi Arabia 19%), Egypt (21%). Lowest: most of sub-Saharan Africa (3-6%) and rural East Asia. The pattern aligns with obesity geography — but Asian populations develop diabetes at lower BMIs than European or African populations due to differences in body composition and insulin sensitivity.
Treatment access is uneven
Insulin (necessary for Type 1, often required for advanced Type 2) costs $5-15/month in countries with strong price negotiation; up to $100-300/month in the US. GLP-1 receptor agonists (semaglutide, tirzepatide) are transforming both diabetes and obesity treatment, but US list prices have been about $1,000 a month, and they remain almost entirely unavailable in low-income countries. The therapeutic frontier is widening, but the access gap is widening with it.
Diabetes prevalence — selected countries (IDF 2021)
% of adults aged 20-79
Show data table
| % prevalence | |
|---|---|
| Pakistan | 31 |
| Mauritius | 22 |
| Kuwait | 25 |
| Saudi Arabia | 18 |
| Egypt | 20 |
| Malaysia | 17 |
| Mexico | 17 |
| USA | 11 |
| Brazil | 11 |
| China | 11 |
| UK | 7 |
| World | 11 |
| Italy | 7 |
| France | 7 |
| India | 9 |
| Ethiopia | 3 |
| Tanzania | 5 |
Key Finding: Pakistan, Pacific Island and Gulf states lead; sub-Saharan Africa still has relatively low prevalence but the fastest projected growth.
People with diabetes globally 1980–2024
Millions of adults
Show data table
| People with diabetes (millions) | |
|---|---|
| 1980 | 108 |
| 1990 | 151 |
| 2000 | 217 |
| 2010 | 366 |
| 2014 | 422 |
| 2019 | 463 |
| 2021 | 537 |
| 2024 | 589 |
Key Finding: More than five-fold since 1980 — driven by population growth, obesity, aging, and improved diagnosis.
Methodology & caveats
Type 1 vs Type 2
Type 1: autoimmune destruction of insulin-producing pancreatic beta cells. Typically onset in childhood/adolescence. Requires insulin replacement for life. Type 2: insulin resistance plus declining beta-cell function. Typically onset in adulthood. Strongly linked to obesity, physical inactivity, age. Gestational diabetes occurs during pregnancy. The 90/10 ratio (Type 2/Type 1) applies globally but with regional variation.
Diagnosed vs undiagnosed
IDF estimates 252 million people (more than 4 in 10 cases) are undiagnosed. Symptoms can be mild until complications develop. HbA1c testing has improved diagnosis where accessible. Public health screening programmes exist in some countries (UK NHS Health Check, US Medicare) — coverage is uneven. The undiagnosed share is highest in sub-Saharan Africa and South Asia.
Complications dominate the burden
Diabetes-related deaths are largely from complications: cardiovascular disease (50% of diabetes deaths), kidney disease, infections, amputations, blindness. Tight glycemic control plus risk-factor management (statins, blood pressure) reduces complications substantially. Modern Type 2 treatment (SGLT-2 inhibitors, GLP-1 agonists) reduces cardiovascular and kidney outcomes independently of glucose control — a major therapeutic shift since 2015.
Why two global totals exist
IDF counts adults aged 20-79 using surveys and modelling; the NCD Risk Factor Collaboration, using a broader definition and adults 18 and over, reported about 828 million people in 2022, of whom a large share had never been treated. The two differ mainly because the second counts people above a blood-glucose or HbA1c threshold or on treatment, at all adult ages. Neither is wrong, but mixing them in one trend exaggerates growth: the 1980 point on this chart comes from WHO/NCD-RisC work and the recent points from IDF.
What would change the picture
The IDF projects about 853 million adults with diabetes by 2050, with the fastest growth in Africa and South Asia. Better survival also raises prevalence, because people live longer with the disease. Generic semaglutide, cheaper insulin and earlier screening could reduce complications, but a fall in prevalence would need lower obesity, which no large country has yet sustained.
Cite this page
GlobeChart. “Diabetes.” Last updated 2026-10-31. https://globechart.com/health/diabetes/
Please also credit the original publisher named under each chart: IDF Diabetes Atlas 10th edition (2021); IDF Diabetes Atlas, NCD-RisC. Spotted an error? Tell us.